Loading…

HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX® B/E

Immune responses to vaccines may be influenced or associated with allelic variants of host genes such as those encoding human leucocyte antigens (HLA). We have molecularly determined the HLA class II DR and DQ gene, allele and haploype profiles in HIV-1 negative ethnic Thai recipients of an HIV-1 pr...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-01, Vol.30 (5), p.832-836
Main Authors: Paris, Robert, Bejrachandra, Sasitorn, Thongcharoen, Prasert, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Sambor, Anna, Gurunathan, Sanjay, Francis, Donald, Ratto-Kim, Silvia, Karnasuta, Chitraporn, de Souza, Mark S, Polonis, Victoria R, Brown, Arthur E, Kim, Jerome H, Stephens, Henry A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune responses to vaccines may be influenced or associated with allelic variants of host genes such as those encoding human leucocyte antigens (HLA). We have molecularly determined the HLA class II DR and DQ gene, allele and haploype profiles in HIV-1 negative ethnic Thai recipients of an HIV-1 prime boost vaccine regimen, designed to induce neutralizing antibody (NAb) responses to HIV-1 CRF01_AE. Non-response to vaccine associated with DRB1*11 (3/32 responders vs. 7/13 non-responders, pc=0.027) and DRB1*16:02 (0/32 responders vs. 4/13 non-responders, pc=0.078) alleles. Furthermore, vaccine recipients with HLA-DQ heterodimers encoded by DQA1*05:01 and DQB1*03:01 alleles, were much less likely to produce NAb (p=0.009). These data suggest that the lack of response to a vaccine designed to induce clade-specific NAb to HIV-1 is associated with the presence of certain HLA class II alleles and heterodimers in some Southeast Asians.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.11.002